SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-140044
Filing Date
2021-11-16
Accepted
2021-11-16 17:07:19
Documents
12
Period of Report
2021-11-15
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2132874d1_8k.htm   iXBRL 8-K 25534
  Complete submission text file 0001104659-21-140044.txt   201673

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tril-20211115.xsd EX-101.SCH 3061
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tril-20211115_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tril-20211115_pre.xml EX-101.PRE 22383
5 EXTRACTED XBRL INSTANCE DOCUMENT tm2132874d1_8k_htm.xml XML 3870
Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627
Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36596 | Film No.: 211417169
SIC: 2834 Pharmaceutical Preparations